The Korean Severe Asthma Registry (KoSAR): real world research in severe asthma

키워드

참고문헌 (69)

1. Eun-young Lee, "Increasing Prevalence and Mortality of Asthma With Age in Korea, 2002–2015: A Nationwide, Population-Based Study", Allergy, Asthma & Immunology Research, 12(3), pp.467~484 (2020), 대한천식알레르기학회
2. Kim SH, "Economic costs for adult asthmatics according to severity and control status in Korean tertiary hospitals", J Asthma, 49, pp.303~309 (2012)
3. Ioana Agache, "Critical Points on the Use of Biologicals in Allergic Diseases and Asthma", Allergy, Asthma & Immunology Research, 12(1), pp.24~41 (2020), 대한천식알레르기학회
4. 김민혜, "Characteristics of Adult Severe Refractory Asthma in Korea Analyzed From the Severe Asthma Registry", Allergy, Asthma & Immunology Research, 11(1), pp.43~54 (2019), 대한천식알레르기학회
5. Bousquet J, "Uniform definition of asthma severity, control, and exacerbations : document presented for the World Health Organization Consultation on Severe Asthma", J Allergy Clin Immunol, 126, pp.926~938 (2010)
6. Bel EH, "Diagnosis and definition of severe refractory asthma : an international consensus statement from the Innovative Medicine Initiative(IMI)", Thorax, 66, pp.910~917 (2011)
7. Chung KF, "International ERS", ATS guidelines on definition, evaluation and treatment of severe asthma, 2014, pp.43, 343~373
8. Ryan D, "Potential severe asthma hidden in UK primary care", J Allergy Clin Immunol Pract, 9, pp.1612~1623 (2021)
9. Byung-Keun Kim, "Evaluation and Management of Difficult-to-Treat and Severe Asthma: An Expert Opinion From the Korean Academy of Asthma, Allergy and Clinical Immunology, the Working Group on Severe Asthma", Allergy, Asthma & Immunology Research, 12(6), pp.910~933 (2020), 대한천식알레르기학회[DOI]
10. Hekking PW, "The prevalence of severe refractory asthma", J Allergy Clin Immunol, 135, pp.896~902 (2015)
11. 김상헌, "Perceptions of Severe Asthma and Asthma-COPD Overlap Syndrome Among Specialists: A Questionnaire Survey", Allergy, Asthma & Immunology Research, 10(3), pp.225~235 (2018), 대한천식알레르기학회
12. Lee YJ, "Health care utilization and direct costs in mild, moderate, and severe adult asthma : a descriptive study using the 2014 South Korean Health Insurance Database", Clin Ther, 39, pp.527~536 (2017)
13. Choi JY, "Current status of asthma care in South Korea : nationwide the Health Insurance Review and Assessment Service database", J Thorac Dis, 9, pp.3208~3214 (2017)
14. 조은정, "Implementation of Asthma Management Guidelines and Possible Barriers in Korea", Journal of Korean Medical Science, 35(12), pp.1~13 (2020), 대한의학회[DOI]
15. van Bragt JJMH, "Characteristics and treatment regimens across ERS SHARP severe asthma registries", Eur Respir J, 55, pp.1901163~ (2020)
16. Lefebvre P, "Acute and chronic systemic corticosteroid-related complications in patients with severe asthma", J Allergy Clin Immunol, 136, pp.1488~1495 (2015)
17. Voorham J, "Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma", Allergy, 74, pp.273~283 (2019)
18. Lee H, "Increased mortality in patients with corticosteroid-dependent asthma : a nationwide population-based study", Eur Respir J, 54, pp.1900804~ (2019)
19. Song WJ, "Patients’ experiences of asthma exacerbation and management : a qualitative study of severe asthma", ERJ Open Res, 7, pp.00528~2020 (2021)
20. Moore WC, "Clinical heterogeneity in the severe asthma research program", Ann Am Thorac Soc, 10(Suppl), pp.S118~S124 (2013)
21. Wenzel SE, "Asthma : defining of the persistent adult phenotypes", Lancet, 368, pp.804~813 (2006)
22. Agache I, "Severe asthma phenotypes and endotypes", Semin Immunol, 46, pp.101301~ (2019)
23. Agache I, "EAACI biologicals guidelines-recommendations for severe asthma", Allergy, 76, pp.14~44 (2021)
24. McDonald VM, "Treatable traits can be identified in a severe asthma registry and predict future exacerbations", Respirology, 24, pp.37~47 (2019)
25. Agusti A, "Treatable traits : toward precision medicine of chronic airway diseases", Eur Respir J, 47, pp.410~419 (2016)
26. Kim Mi-Ae, "Specialist Perception of Severe Asthma in Korea: A Questionnaire Survey", Allergy, Asthma & Immunology Research, 13(3), pp.507~514 (2021), 대한천식알레르기학회[DOI]
27. Lee H, "Characteristics of specialist-diagnosed asthma-COPD overlap in severe asthma : observations from the Korean Severe Asthma Registry(KoSAR)", Allergy, 76, pp.223~232 (2021)
28. Kondo M, "Therapeutic approaches of asthma and COPD overlap", Allergol Int, 67, pp.187~190 (2018)
29. Holguin F, "Management of severe asthma : a European Respiratory Society", American Thoracic Society guideline, 2020, pp.55, 1900588~
30. "Global Strategy for Asthma Management and Prevention" (2022)[URL]
31. FitzGerald JM, "Recognition and management of severe asthma : a Canadian Thoracic Society position statement", Can J Respir Crit Care Sleep Med, 1, pp.199~221 (2017)
32. Lin J, "Chinese expert consensus on diagnosis and management of severe asthma", J Thorac Dis, 10, pp.7020~7044 (2018)
33. Garcia G, "Severe asthma : adding new evidence : Latin American Thoracic Society", ERJ Open Res, 7, pp.00318~2020 (2021)
34. Kerstjens HA, "Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma(IRIDIUM) : a randomised, double-blind, controlled phase 3 study", Lancet Respir Med, 8, pp.1000~1012 (2020)
35. Lee LA, "Efficacy and safety of once-daily single-inhaler triple therapy(FF", UMEC, VI in patients with inadequately controlled asthma(CAPTAIN) : a double-blind, randomised, phase 3A trial, pp.Lancet Respir Med, 2021[DOI]
36. Virchow JC, "Single inhaler extrafine triple therapy in uncontrolled asthma(TRIMARAN and TRIGGER) : two double-blind, parallel-group, randomised, controlled phase 3 trials", Lancet, 394, pp.1737~1749 (2019)
37. Sferrazza Papa GF, "Role and challenges of severe asthma services : insights from the UK registry", Minerva Med, 108(3 Suppl 1), pp.13~17 (2017)
38. Gibeon D, "Dedicated severe asthma services improve health-care use and quality of life", Chest, 148, pp.870~876 (2015)
39. Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC), "2020Focused updates to the asthma management guidelines : a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group", J Allergy Clin Immunol, 146, pp.1217~1270 (2020)
40. McDonald VM, "How to set up a severe asthma service", Respirology, 16, pp.900~911 (2011)
41. Burke H, "A multidisciplinary team case management approach reduces the burden of frequent asthma admissions", ERJ Open Res, 2, pp.00039~2016 (2016)
42. Gamble J, "A study of a multi-level intervention to improve non-adherence in difficult to control asthma", Respir Med, 105, pp.1308~1315 (2011)
43. FitzGerald JM, "The challenges and opportunities of maximizing the benefits of severe asthma registries", J Allergy Clin Immunol Pract, 7, pp.1469~1470 (2019)
44. Heaney LG, "Refractory asthma in the UK : cross-sectional findings from a UK multicentre registry", Thorax, 65, pp.787~794 (2010)
45. Senna G, "SANI-Severe Asthma Network in Italy : a way forward to monitor severe asthma", Clin Mol Allergy, 15, pp.9~ (2017)
46. Pretolani M, "Clinical and biological characteristics of the French COBRA cohort of adult subjects with asthma", Eur Respir J, 50, pp.1700019~ (2017)
47. Schleich F, "Heterogeneity of phenotypes in severe asthmatics : the Belgian Severe Asthma Registry(BSAR)", Respir Med, 108, pp.1723~1732 (2014)
48. Vennera Mdel C, "Omalizumab therapy in severe asthma : experience from the Spanish registry : some new approaches", J Asthma, 49, pp.416~422 (2012)
49. Sa-Sousa A, "The Portuguese Severe Asthma Registry : development, features, and data sharing policies", Biomed Res Int, 2018, pp.1495039~ (2018)
50. Doberer D, "The Austrian Severe Asthma Registry", Wien Klin Wochenschr, 127, pp.821~822 (2015)
51. "Pneumologie", 2012, 341~344
52. Nenasheva N, "Characteristics of patients with severe asthma in the Russian Federation-the Russian Severe Asthma Registry", Am J Respir Crit Care Med, 199, pp.A1337~ (2019)
53. Ambrose CS, "The CHRONICLE study of US adults with subspecialist-treated severe asthma : objectives, design, and initial results", Pragmat Obs Res, 11, pp.77~90 (2020)
54. "Australasian Severe Asthma Registry" (2022)[URL]
55. Djukanovic R, "The Severe Heterogeneous Asthma Research collaboration, Patient-centred(SHARP)ERS Clinical Research Collaboration : a new dawn in asthma research", Eur Respir J, 52, pp.1801671~ (2018)
56. Kirenga B, "Phenotypic characteristics and asthma severity in an East African cohort of adults and adolescents with asthma : findings from the African severe asthma project", BMJ Open Respir Res, 7, pp.e000484~ (2020)
57. ISAR Study Group, "International Severe Asthma Registry : mission statement", Chest, 157, pp.805~814 (2020)
58. Wenzel SE, "Severe asthma:lessons from the Severe Asthma Research Program", J Allergy Clin Immunol, 119, pp.14~21 (2007)
59. Jarjour NN, "Severe asthma : lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program", Am J Respir Crit Care Med, 185, pp.356~362 (2012)
60. Shaw DE, "Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort", Eur Respir J, 46, pp.1308~1321 (2015)
61. Wang E, "Characterization of severe asthma worldwide : data from the International Severe Asthma Registry", Chest, 157, pp.790~804 (2020)
62. Agache I, "Efficacy and safety of treatment with biologicals(benralizumab, dupilumab and omalizumab)for severe allergic asthma : a systematic review for the EAACI Guidelines : recommendations on the use of biologicals in severe asthma", Allergy, 75, pp.1043~1057 (2020)
63. Agache I, "A systematic review for the EAACI guidelines : recommendations on the use of biologicals in severe asthma", Allergy, 75, pp.1023~1042 (2020)
64. Jae-Woo Jung, "Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma", The Korean Journal of Internal Medicine, 36(4), pp.1001~1013 (2021), 대한내과학회[DOI]
65. Gibson PG, "Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities : the Australian Xolair Registry", Intern Med J, 46, pp.1054~1062 (2016)
66. Harvey ES, "Mepolizumab effectiveness and identification of super-responders in severe asthma", Eur Respir J, 55, pp.1902420~ (2020)
67. Kavanagh JE, "Real-world effectiveness and the characteristics of a"super-responder"to mepolizumab in severe eosinophilic asthma", Chest, 158, pp.491~500 (2020)
68. de Llano LP, "Effects of omalizumab in non-atopic asthma : results from a Spanish multicenter registry", J Asthma, 50, pp.296~301 (2013)
69. Menzies-Gow A, "A charter to improve patient care in severe asthma", Adv Ther, 35, pp.1485~1496 (2018)

관련 논문AI추천